Advanced Energy Industries, Inc. (NASDAQ:AEIS), a global leader in precision power, today announced it has acquired Excelsys Holdings Limited (Excelsys), a privately held company based in Cork, Ireland. Excelsys designs and manufactures high efficiency and highly reliable power supplies for a variety of industrial markets. Its modular and user-configurable technology brings new and differentiated capabilities to Advanced Energy’s existing product portfolio. This new product line allows Advanced Energy® (AE®) to expand its addressable market ? offering new applications and serving a larger worldwide customer base.
“Today’s acquisition of Excelsys is part of our ongoing strategy to grow and diversify our industrial business by adding new power products and applications to our robust portfolio,” said Yuval Wasserman, President and CEO. “With a complementary platform of electronic power supplies for mission-critical applications, Excelsys joins our Specialty Power organization ? increasing our presence in new areas within medical equipment, metrology, lasers and general industrial applications.”
“We are excited to join Advanced Energy, a global leader in precision power conversion,” said Gary Duffy Excelsys leader and former CEO. “Through the combined companies, our customers will now have access to a host of additional value-added products and services as we work together to expand Advanced Energy’s leading, competitive position worldwide and maintain the high levels of reliability and customer service.”
Tower Semiconductor announced that it has signed silicon photonics agreements valued at $1.3 billion for…
The report is based on a survey of 150 CISOs and senior cybersecurity leaders from…
More than 200,000 voters will cast ballots using a secure and cryptographically verified online voting…
The multi-center study, involving 2,000 patients, will validate the CORA system - a breakthrough AI…
Molex, a global electronics leader and connectivity innovator, has completed the acquisition of Teramount Ltd.,…
This agreement marks the third expansion of its collaboration with AstraZeneca, building on collaborations in…